Diabetes Care, Vol 23, Issue 5 644-649, Copyright © 2000 by American Diabetes Association

ARTICLES

Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo

L Heinemann, R Linkeschova, K Rave, B Hompesch, M Sedlak and T Heise
Department of Metabolic Diseases and Nutrition, the World Health Organization Collaborating Centre for Diabetes, Heinrich-Heine University, Dusseldorf, Germany. lutz.heinemann@profil-research.de

OBJECTIVE: To study the pharmacodynamic properties of the subcutaneously injected long-acting insulin analog HOE901 (30 microg/ml zinc) in comparison with those of NPH insulin and placebo. RESEARCH DESIGN AND METHODS: In this single-center double-blind euglycemic glucose clamp study, 15 healthy male volunteers (aged 27 +/- 4 years, BMI 22.2 +/- 1.8 kg/m2) received single subcutaneous injections of 0.4 U/kg body wt of HOE901, NPH insulin, or placebo on 3 study days in a randomized order. The necessary glucose infusion rates (GIRs) to keep blood glucose concentrations constant at 5.0 mmol/l were determined over a 30-h period after administration. RESULTS: The injection of HOE901 did not induce the pronounced peak in metabolic activity observed with NPH insulin (GIRmax 5.3 +/- 1.1 vs. 7.7 +/- 1.3 mg x kg(-1) x min(-1)) (P < 0.05); after an initial rise, metabolic activity was rather constant over the study period. This lack of peak was confirmed by a lower glucose consumption in the first 4 h after injection (area under the curve from 0 to 4 h [AUC(0-4 h)] 1.02 +/- 0.34 vs. 1.48 +/- 0.34 g/kg) (P < 0.001) with HOE901, as compared with NPH insulin. In this single-dose study, the metabolic effect measured over a period of 30 h was lower with HOE901 than with NPH insulin (AUC(0-30 h) 7.93 +/- 1.82 vs. 9.24 +/- 1.29 g/kg) (P < 0.05). CONCLUSIONS: This study shows that the soluble long-acting insulin analog HOE901 induces a smoother metabolic effect than NPH insulin, from which a better substitution of basal insulin requirements may follow.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				F. Porcellati, P. Rossetti, N. B. Ricci, S. Pampanelli, E. Torlone, S. H. Campos, A. M. Andreoli, G. B. Bolli, and C. G. Fanelli Pharmacokinetics and Pharmacodynamics of the Long-Acting Insulin Analog Glargine After 1 Week of Use Compared With Its First Administration in Subjects With Type 1 Diabetes Diabetes Care, May 1, 2007; 30(5): 1261 - 1263. [Full Text] [PDF]

				F. M Regan and D. B Dunger Use of new insulins in children Arch. Dis. Child. Ed. Pract., August 1, 2006; 91(2): ep47 - ep53. [Full Text] [PDF]

				C. Robertson Physiologic insulin replacement in type 2 diabetes: optimizing postprandial glucose control. The Diabetes Educator, May 1, 2006; 32(3): 423 - 432. [Abstract] [Full Text] [PDF]

				J. Rosenstock, G. Dailey, M. Massi-Benedetti, A. Fritsche, Z. Lin, and A. Salzman Reduced Hypoglycemia Risk With Insulin Glargine: A meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes Diabetes Care, April 1, 2005; 28(4): 950 - 955. [Abstract] [Full Text] [PDF]

				A. N Dixon and S. C Bain Nausea and vomiting due to insulin glargine in patient with type 1 diabetes mellitus BMJ, February 26, 2005; 330(7489): 455 - 455. [Full Text] [PDF]

				H. U. Janka, G. Plewe, M. C. Riddle, C. Kliebe-Frisch, M. A. Schweitzer, and H. Yki-Jarvinen Comparison of Basal Insulin Added to Oral Agents Versus Twice-Daily Premixed Insulin as Initial Insulin Therapy for Type 2 Diabetes Diabetes Care, February 1, 2005; 28(2): 254 - 259. [Abstract] [Full Text] [PDF]

				E. Standl, S. Maxeiner, S. Raptis, Z. Karimi-Anderesi, M. A. Schweitzer, and the HOE901/4009 Study Group Good Glycemic Control With Flexibility in Timing of Basal Insulin Supply: A 24-week comparison of insulin glargine given once daily in the morning or at bedtime in combination with morning glimepiride Diabetes Care, February 1, 2005; 28(2): 419 - 420. [Full Text] [PDF]

				I. B. Hirsch Insulin Analogues N. Engl. J. Med., January 13, 2005; 352(2): 174 - 183. [Full Text] [PDF]

				T. Heise, L. Nosek, B. B. Ronn, L. Endahl, L. Heinemann, C. Kapitza, and E. Draeger Lower Within-Subject Variability of Insulin Detemir in Comparison to NPH Insulin and Insulin Glargine in People With Type 1 Diabetes Diabetes, June 1, 2004; 53(6): 1614 - 1620. [Abstract] [Full Text] [PDF]

				M. C. Riddle, J. Rosenstock, and J. Gerich The Treat-to-Target Trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients Diabetes Care, November 1, 2003; 26(11): 3080 - 3086. [Abstract] [Full Text] [PDF]

				T. Danne, K. Lupke, K. Walte, W. von Schuetz, and M.-A. Gall Insulin Detemir Is Characterized by a Consistent Pharmacokinetic Profile Across Age-Groups in Children, Adolescents, and Adults With Type 1 Diabetes Diabetes Care, November 1, 2003; 26(11): 3087 - 3092. [Abstract] [Full Text] [PDF]

				N. P. Murphy, S. M. Keane, K. K. Ong, M. Ford-Adams, J. A. Edge, C. L. Acerini, and D. B. Dunger Randomized Cross-Over Trial of Insulin Glargine Plus Lispro or NPH Insulin Plus Regular Human Insulin in Adolescents With Type 1 Diabetes on Intensive Insulin Regimens Diabetes Care, March 1, 2003; 26(3): 799 - 804. [Abstract] [Full Text] [PDF]

				S. Mudaliar, P. Mohideen, R. Deutsch, T. P. Ciaraldi, D. Armstrong, B. Kim, X. Sha, and R. R. Henry Intravenous Glargine and Regular Insulin Have Similar Effects on Endogenous Glucose Output and Peripheral Activation/Deactivation Kinetic Profiles Diabetes Care, September 1, 2002; 25(9): 1597 - 1602. [Abstract] [Full Text] [PDF]

				E. Schober, E. Schoenle, J. Van Dyk, and K. Wernicke-Panten Comparative Trial Between Insulin Glargine and NPH Insulin in Children and Adolescents With Type 1 Diabetes Diabetes Care, November 1, 2001; 24(11): 2005 - 2006. [Full Text] [PDF]

				Z. Vajo, J. Fawcett, and W. C. Duckworth Recombinant DNA Technology in the Treatment of Diabetes: Insulin Analogs Endocr. Rev., October 1, 2001; 22(5): 706 - 717. [Abstract] [Full Text] [PDF]